Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IVVD NASDAQ:LXEO NASDAQ:MEIP NASDAQ:NMRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVVDInvivyd$1.39-5.4%$1.57$0.48▼$3.07$415.72M0.713.06 million shs2.39 million shsLXEOLexeo Therapeutics$5.96+2.8%$6.28$2.43▼$10.99$455.42M1.52714,843 shs416,492 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.92▼$9.00$104.72M0.38919,067 shs3.98 million shsNMRANeumora Therapeutics$2.30-0.4%$2.56$0.61▼$3.65$422.01M3.021.40 million shs699,258 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVVDInvivyd0.00%+4.11%+18.75%-19.15%+141.88%LXEOLexeo Therapeutics0.00%+2.49%+0.87%-23.27%+24.35%MEIPMEI Pharma0.00%0.00%0.00%0.00%+56.32%NMRANeumora Therapeutics0.00%+9.91%+22.00%+19.61%+214.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIVVDInvivyd$1.39-5.4%$1.57$0.48▼$3.07$415.72M0.713.06 million shs2.39 million shsLXEOLexeo Therapeutics$5.96+2.8%$6.28$2.43▼$10.99$455.42M1.52714,843 shs416,492 shsMEIPMEI Pharma$3.19+14.7%$3.98$1.92▼$9.00$104.72M0.38919,067 shs3.98 million shsNMRANeumora Therapeutics$2.30-0.4%$2.56$0.61▼$3.65$422.01M3.021.40 million shs699,258 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIVVDInvivyd0.00%+4.11%+18.75%-19.15%+141.88%LXEOLexeo Therapeutics0.00%+2.49%+0.87%-23.27%+24.35%MEIPMEI Pharma0.00%0.00%0.00%0.00%+56.32%NMRANeumora Therapeutics0.00%+9.91%+22.00%+19.61%+214.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIVVDInvivyd 2.33Hold$8.00475.54% UpsideLXEOLexeo Therapeutics 2.89Moderate Buy$18.88216.69% UpsideMEIPMEI Pharma 0.00N/AN/AN/ANMRANeumora Therapeutics 2.56Moderate Buy$7.67233.33% UpsideCurrent Analyst Ratings BreakdownLatest MEIP, LXEO, IVVD, and NMRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/29/2026IVVDInvivyd Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NMRANeumora Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026NMRANeumora Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.003/31/2026NMRANeumora Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.002/26/2026IVVDInvivyd BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.002/17/2026NMRANeumora Therapeutics William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIVVDInvivyd$53.43M7.36N/AN/A$1.04 per share1.34LXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/AMEIPMEI PharmaN/AN/A$6.25 per share0.51$4.96 per shareN/ANMRANeumora TherapeuticsN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIVVDInvivyd-$52.49M-$0.32N/AN/AN/A-98.25%-48.65%-34.48%5/7/2026 (Estimated)LXEOLexeo Therapeutics-$99.96M-$2.19N/AN/AN/AN/A-67.33%-55.98%5/11/2026 (Estimated)MEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%N/ANMRANeumora Therapeutics-$236.93M-$1.45N/AN/AN/AN/A-146.41%-111.57%5/11/2026 (Estimated)Latest MEIP, LXEO, IVVD, and NMRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29N/AN/AN/AN/AN/A5/11/2026Q1 2026NMRANeumora Therapeutics-$0.32N/AN/AN/AN/AN/A5/7/2026Q1 2026IVVDInvivyd-$0.08N/AN/AN/A$18.04 millionN/A3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/A3/30/2026Q4 2025NMRANeumora Therapeutics-$0.34-$0.35-$0.01-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIVVDInvivydN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ANMRANeumora TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIVVDInvivydN/A7.247.24LXEOLexeo TherapeuticsN/A11.2111.21MEIPMEI PharmaN/A16.7816.78NMRANeumora Therapeutics0.525.875.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIVVDInvivyd70.36%LXEOLexeo Therapeutics60.67%MEIPMEI Pharma52.38%NMRANeumora Therapeutics47.65%Insider OwnershipCompanyInsider OwnershipIVVDInvivyd12.25%LXEOLexeo Therapeutics5.30%MEIPMEI Pharma3.12%NMRANeumora Therapeutics26.94%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIVVDInvivyd100282.80 million248.16 millionOptionableLXEOLexeo Therapeutics5878.52 million74.36 millionNot OptionableMEIPMEI Pharma10032.84 million31.81 millionOptionableNMRANeumora Therapeutics108182.69 million133.47 millionOptionableMEIP, LXEO, IVVD, and NMRA HeadlinesRecent News About These CompaniesNeumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on MondayMay 4 at 10:22 AM | marketbeat.comNeumora Therapeutics, Inc. (NMRA) Gets a Buy from GuggenheimApril 25, 2026 | theglobeandmail.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by AnalystsApril 22, 2026 | marketbeat.comNeumora: Deep Pipeline and Near‑Term Clinical Catalysts Support Attractive Risk‑Reward and Buy RatingApril 14, 2026 | tipranks.comNeumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to ExplodeApril 12, 2026 | insidermonkey.comNeumora Therapeutics (NMRA) price target increased by 19.25% to 9.33April 10, 2026 | msn.comNeumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare ConferenceApril 6, 2026 | globenewswire.comNMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmApril 1, 2026 | globenewswire.comNeumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call SummaryApril 1, 2026 | finance.yahoo.comNeumora Therapeutics Maps High-Stakes Catalyst Road AheadMarch 31, 2026 | tipranks.comNeumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital AccessMarch 31, 2026 | tipranks.comNeumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ...March 30, 2026 | finance.yahoo.comNeumora Therapeutics: Charting a Course for Breakthroughs in Brain DiseasesMarch 30, 2026 | news.themarketisopen.comNNeumora tops Q4 earnings forecasts as pipeline advances, shares slipMarch 30, 2026 | msn.comNeumora Therapeutics: Downgrading After Navacaprant Development SetbackMarch 30, 2026 | seekingalpha.comNeumora Therapeutics, Inc. (NMRA) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comNeumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comNeumora Therapeutics (NMRA) price target decreased by 16.15% to 7.82March 28, 2026 | msn.comNeumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analystsMarch 27, 2026 | msn.comNMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmMarch 19, 2026 | businesswire.comNeumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026March 16, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMEIP, LXEO, IVVD, and NMRA Company DescriptionsInvivyd NASDAQ:IVVD$1.39 -0.08 (-5.44%) Closing price 04:00 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.Lexeo Therapeutics NASDAQ:LXEO$5.96 +0.16 (+2.76%) Closing price 04:00 PM EasternExtended Trading$6.00 +0.04 (+0.67%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.MEI Pharma NASDAQ:MEIPMEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Neumora Therapeutics NASDAQ:NMRA$2.30 -0.01 (-0.43%) Closing price 04:00 PM EasternExtended Trading$2.27 -0.03 (-1.30%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
